Bio Blast Pharma Aktie
WKN DE: A119KH / ISIN: IL0011319527
|
07.07.2026 14:28:12
|
Enlivex Launches 1-for-15 Reverse Stock Split
(RTTNews) - Enlivex Ltd. (ENLV), a clinical-stage immunotherapy company, Tuesday announced a 1-for-15 reverse split of its ordinary shares where every 15 shares will automatically be combined into one ordinary share.
Beginning on July 9, the common shares will trade on a split adjusted basis under the symbol "ENLV" on Nasdaq.
Due to the reverse split, the number of ordinary shares will ratably be reduced from 2,375,000,000 to 158,333,334, and the par value of each ordinary share will ratably increase from NIS 0.40 to NIS 6.00 and the number of Enlivex's issued and outstanding ordinary shares will decrease from 252,480,222 to approximately 16,832,015.
In pre-market activity, ENLV shares were trading at $0.43, down 16.03% on the Nasdaq.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio Blast Pharma Ltd.
|
26.03.26 |
EQS-News: Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 (EQS Group) |
Analysen zu Bio Blast Pharma Ltd.
Aktien in diesem Artikel
| Bio Blast Pharma Ltd. | 4,02 | 2,55% |
|